Latest Kaiser Health News Stories
A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
A 22-year old man from Orange County, Calif., alleges in a lawsuit that his health insurer stopped paying for a crucial — and expensive — immunotherapy drug, leading him to become seriously ill. Treatments for patients with similar conditions are increasingly denied or interrupted, experts and patient advocates say.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
You might save money on premiums with a high-deductible health plan only to find you’re spending more on the back end. These tips will help you minimize your expenses for medical treatment and prescriptions.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
The opioid addiction crisis has led to a crackdown on prescriptions for chronic pain patients, who are increasingly given less addictive painkillers along with referrals for acupuncture, physical therapy, massage and even yoga.
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.